NCT05119933: A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Part 1 of the study & they must have a metastatic solid tumor positive for KRAS G12C
Exclusions: Patients who have received prior treatment with KRAS G12C targeted agents; Patients who have received 4 or more lines of prior therapy; Patients with any central nervous system (CNS) involvement (e.g. brain metastasis or leptomeningeal disease)

Comments are closed.

Up ↑